Onconic Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	53,392	14,838	21,056	95	60
Revenue Growth (YoY)	259.82%	-29.53%	22064.25%	58.33%	-
Cost of Revenue	10.96	3.78	2.37	14,933	8,402
Gross Profit	53,381	14,835	21,054	-14,838	-8,342
Selling, General & Admin	30,370	8,087	2,463	-	-
Research & Development	9,721	10,929	15,761	-	-
Amortization of Goodwill & Intangibles	1.18	1.18	1.18	-	-
Other Operating Expenses	142.77	164.15	138.3	-	-
Operating Expenses	40,762	19,632	18,823	-	-
Operating Income	12,619	-4,798	2,231	-14,838	-8,342
Interest Expense	-11.68	-664.16	-1,776	-1,078	-6,831
Interest & Investment Income	1,387	942.63	863.01	1,431	18.85
Currency Exchange Gain (Loss)	-282.81	2,020	-79.65	-	-
Other Non Operating Income (Expenses)	1.65	-7,442	-576.09	52.86	5.74
EBT Excluding Unusual Items	13,713	-9,942	662.51	-14,432	-15,149
Gain (Loss) on Sale of Investments	10.77	-	-	-	-
Gain (Loss) on Sale of Assets	-	-	-0.7	-	-
Pretax Income	13,724	-9,942	661.81	-14,432	-15,149
Income Tax Expense	-2,060	-1,849	-1,021	-	-
Net Income	15,784	-8,093	1,682	-14,432	-15,149
Net Income to Common	15,784	-8,093	1,682	-14,432	-15,149
Shares Outstanding (Basic)	44	33	23	23	23
Shares Outstanding (Diluted)	45	33	23	23	23
Shares Change (YoY)	38.72%	41.46%	-0.00%	0.94%	-
EPS (Basic)	358.67	-247.45	72.78	-624.23	-661.40
EPS (Diluted)	347.92	-247.45	72.78	-624.23	-661.40
Free Cash Flow	11,092	-7,982	2,983	-17,536	-8,861
Free Cash Flow Per Share	244.50	-244.07	129.01	-758.49	-386.90
Gross Margin	99.98%	99.98%	99.99%	-	-
Operating Margin	23.64%	-32.33%	10.60%	-15618.48%	-13903.24%
Profit Margin	29.56%	-54.54%	7.99%	-15191.48%	-25247.72%
Free Cash Flow Margin	20.77%	-53.79%	14.16%	-18458.96%	-14769.11%
EBITDA	13,148	-4,345	2,691	-14,770	-8,292
EBITDA Margin	24.63%	-29.28%	12.78%	-	-
D&A For EBITDA	528.44	452.67	460.13	67.43	49.65
EBIT	12,619	-4,798	2,231	-14,838	-8,342
EBIT Margin	23.64%	-32.33%	10.60%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.